AOD-9604 (5mg – 10mg)

AOD-9604: Research Peptide for Lipid Metabolism Studies

AOD-9604 is a 16-amino-acid synthetic peptide fragment corresponding to the C-terminal region (residues 177–191) of human growth hormone (hGH). Laboratory studies investigate this modified fragment for its interactions with lipid catabolism pathways in preclinical models PubMed. With a molecular weight of approximately 1815.1 Da, the peptide includes an additional tyrosine residue at the N-terminus for structural stability Endocrine Society.

Mechanism of Lipid Pathway Interactions

Research examines AOD-9604 in cellular and animal models to characterize its effects on lipolytic signaling. Studies investigate:

• β3-adrenergic receptor pathway activation in cultured adipocyte models PubMed

• Hormone-sensitive lipase (HSL) signaling in laboratory cell systems Endocrine Society

• Mitochondrial β-oxidation markers including carnitine palmitoyltransferase-1 (CPT-1) expression in rodent obesity models JOFEM

• Acetyl-CoA carboxylase (ACC) pathway modulation in hepatocyte culture systems JOFEM

In vitro models measure glycerol release from adipocytes as an endpoint for lipolytic pathway activity PubMed. Animal research examines plasma triglyceride markers and fatty acid oxidation pathways without activating insulin-like growth factor-1 (IGF-1) signaling Endocrine Society. Human evidence remains limited JOFEM.

Laboratory Research Applications

AOD-9604 serves as an investigational tool in controlled research environments:

• Adipocyte lipolysis pathway studies examining β3-adrenergic signaling mechanisms PubMed

• Lipid homeostasis investigations measuring peroxisome proliferator-activated receptor-alpha (PPAR-α) expression in laboratory models JOFEM

• Comparative peptide research distinguishing growth hormone fragment activity from full hGH in preclinical obesity models Endocrine Society

• Mitochondrial dynamics studies examining membrane potential markers in metabolic research settings JOFEM

These applications are confined to laboratory investigation by qualified researchers. AOD-9604 is not approved by regulatory authorities for human consumption or veterinary use JOFEM.

Research Study Design Considerations

Preclinical investigations employ obese rodent models (e.g., Zucker rats) to examine lipid metabolism endpoints over multi-week study periods Endocrine Society. Measured research endpoints include adipose tissue markers, plasma lipid profiles, and gene expression for metabolic enzymes JOFEM. Early-phase human trials examined safety and tolerability parameters, though efficacy data showed no statistical significance compared to control groups JOFEM. Researchers must obtain institutional approvals and comply with local regulatory requirements before initiating studies.

Reconstitution and Handling

AOD-9604 may exhibit coagulation upon reconstitution, which occurs as a characteristic of high-purity peptide compounds. Contact Protide Health support for laboratory handling guidance if needed.

References

1. Heffernan M, et al. The effects of human GH and its lipolytic fragment. Endocrinology. PubMed

2. Ng FM, et al. Effects of Human GH and Its Lipolytic Fragment. Endocrine Society

3. Ng FM, et al. Safety and Metabolism of AOD9604. JOFEM

4. Stier H, et al. Safety and Tolerability of AOD9604. JOFEM